key: cord-0803104-ejv4yevj
authors: Alamdari, Daryoush Hamidi; Moghaddam, Ahmad Bagheri; Amini, Shahram; Keramati, Mohammad Reza; Zarmehri, Azam Moradi; Alamdari, Aida Hamidi; Damsaz, Mohammadamin; Banpour, Hamed; Yarahmadi, Amir; Koliakos, George
title: Application of methylene blue -vitamin C –N-acetyl cysteine for treatment of critically ill COVID-19 patients, report of a phase-I clinical trial()
date: 2020-08-20
journal: Eur J Pharmacol
DOI: 10.1016/j.ejphar.2020.173494
sha: 1b55ab515e0be6735805261360b84e09ab09e9f9
doc_id: 803104
cord_uid: ejv4yevj

COVID-19 is a global catastrophic event that causes severe acute respiratory syndrome. The mechanism of the disease remains unclear, and hypoxia is one of the main complications. There is no currently approved protocol for treatment. The microbial threat as induced by COVID-19 causes the activation of macrophages to produce a huge amount of inflammatory molecules and nitric oxide (NO). Activation of macrophages population into a pro-inflammatory phenotype induces a self-reinforcing cycle. Oxidative stress and NO contribute to this cycle, establishing a cascade inflammatory state that can kill the patient. Interrupting this vicious cycle by a simple remedy may save critical patients’ lives. Nitrite, nitrate (the metabolites of NO), methemoglobin, and prooxidant-antioxidant-balance levels were measured in 25 ICU COVID-19 patients and 25 healthy individuals. As the last therapeutic option, five patients were administered methylene blue-vitamin C–N-acetyl Cysteine (MCN). Nitrite, nitrate, methemoglobin, and oxidative stress were significantly increased in patients in comparison to healthy individuals. Four of the five patients responded well to treatment. In conclusion, NO, methemoglobin and oxidative stress may play a central role in the pathogenesis of critical COVID-19 disease. MCN treatment seems to increase the survival rate of these patients. Considering the vicious cycle of macrophage activation leading to deadly NO, oxidative stress, and cytokine cascade syndrome; the therapeutic effect of MCN seems to be reasonable. Accordingly, a wider clinical trial has been designed. It should be noted that the protocol is using the low-cost drugs which the FDA approved for other diseases. TRIAL REGISTRATION NUMBER: NCT04370288.

The rapid spread of the deadly COVID-19 caused by SARS-CoV-2 is currently a nightmare for 65 all the world. COVID-19 is responsible for this catastrophic pandemic disease. The WHO 66 reported that 14% of infected patients have severe disease and require hospitalization, 5% of 67 infected patients have very severe conditions and require intensive care admission (mostly for 68 ventilation) and 4% of infected patients die (Grech, 2020) . 69 The huge efforts have been done for finding the pathophysiology and treatment of critical The SARS-CoV-2 causes the activation of macrophages to produce a huge amount of 82 inflammatory molecules, which cytokine storm syndrome is the main cause of the death in 83 COVID-19 patients (Alunno et al., 2020). Also, it is known in other diseases that overproduction of inducible nitric oxide (iNO) (Miclescu and Wiklund, 2010) Table 1 . The data of patients before and after treatment by methylene blue are 137 presented in Table 2 . 13. On the same day of MB administration, the patient was decannulated and tracheostomy was 166 removed and oxygen therapy was started by a reserve bag mask.

14. Antibiotic therapy was continued and dexamethasone (8 mg QID) was started. 168 15. The day after starting MB therapy, the patient had a large volume of tracheal secretion from 169 the tracheostomy site, but SPO2 was 90-92% on high flow oxygen. 17. From the fourth day after MB therapy, dexamethasone was tapered and patient consciousness 173 was improved, the tracheal secretion was decreased but the patient had a low degree of fever.

18. On the sixth day after starting methylene blue, oxygen therapy was discontinued.

19. On the twenty-third day, he was discharged from ICU. 16. On the fifth day of MB therapy, the patient did not need oxygen therapy and SPO2 was 90-281 92% and she was completely awake and oral feeding was started. 282 17. On the seventh day, she was discharged from ICU. 

This study showed that nitrite, nitrate, met-Hb, and oxidative stress are significantly increased 288 in patients in comparison to healthy individuals. This is compatible with the inflammatory 289 process and macrophage activation that has been observed in COVID 19 disease (Alunno et al., 

It is reported that following cytokine administration, increased levels of nitrite has been detected 299 in many diseases such as sepsis, ulcerative colitis, arthritis, multiple sclerosis, and type I diabetes 300 (Hibbs et al., 1992) . Also, excessive NO is produced during the course of a variety of The data are presented as mean ± S.D. a There was a significant difference between patients and 529 HI (p<0.05). The data are presented as mean ± S.D. a There was a significant difference between patients and 540 HI (p<0.05).

Treatment algorithm for COVID-19: a multidisciplinary 465 point of view

Unknown unknowns-COVID-19 and potential global mortality

Reactive Oxygen Species in Venous

The Application of a Reduced Dye Used in Orthopedics as a Novel Treatment 472 against Coronavirus (COVID-19): A Suggested Therapeutic Protocol. Archives of Bone and Joint 473 Surgery

Evidence for cytokine-inducible nitric oxide synthesis from L-arginine 476 in patients receiving interleukin-2 therapy

Plasma nitrite reflects constitutive nitric oxide synthase activity in 479 mammals

Nitric oxide inhalation as an interventional rescue therapy for COVID-481 19-induced acute respiratory distress syndrome

The relationship of COVID-19 severity with cardiovascular disease and its traditional risk 489 factors: A systematic review and meta-analysis

Henry's Clinical Diagnosis and Management by Laboratory Methods: First South 491

Pathological inflammation in patients with COVID-19: a key role for 493 monocytes and macrophages

Methylene blue, an old drug with new indications

A practical method for the 497 accurate determination of methemoglobin in blood containing carboxyhemoglobin

Flow Cytometric Measurement Of ROS Production In 500

Macrophages In Response To FcγR Cross-linking. JoVE

Ceruloplasmin is a NO oxidase and nitrite synthase that determines 503 endocrine NO homeostasis

Regulation of 505 nitrite transport in red blood cells by hemoglobin oxygen fractional saturation. American Journal of dysfunction in multiple organ dysfunction syndrome. The American journal of emergency medicine 26

A prospective evaluation of methylene blue and gentian violet dressing for 514 management of chronic wounds with local infection

Therapeutic and prophylactic use of reduced forms of 516 pharmaceutical compounds

The role of imaging in 518 2019 novel coronavirus pneumonia (COVID-19)

Effect of lycopene on serum nitrite-nitrate levels in 520 diabetic rats